Form Type:  SC 13D
Filing Date:  11/6/2019 
CIK:  0001783183 
Address:  2150 E. LAKE COOK ROAD, SUITE 800 
City, State, Zip:  BUFFALO GROVE, Illinois 60089 
Telephone:  650-325-5156 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-1.57 (-6.96%)  
Trade Time: 
Dec 11  
Market Cap: 
Trade PHAT now with 

© 2019  
Description of Business
We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of Helicobacter pylori, or H. pylori,infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500 million in net sales in its fourth full year on the market since its approval in Japan in late 2014.
Register and access this filing in: